Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Brief Summary: This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: methotrexate, Drug: Placebo, triple | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: Sulfasalazine, Drug: Hydroxychloroquine, Drug: Placebo, etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Sulfasalazine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Hydroxychloroquine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo, triple; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo, etanercept; Assigned to Arm(s): Arm 2
B: Arm Label: Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Arm Label: Infliximab + MTX (DB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab (INF) + MTX, DB | Arm Label: Placebo + MTX (DB); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (PLA) + MTX, DB | Arm Label: Placebo + MTX switched to abatacept + MTX (DB); Type: EXPERIMENTAL; Interventions: Drug: PLA + MTX switched to ABA+ MTX, DB | Arm Label: Abatacept (open-label); Type: EXPERIMENTAL; Interventions: Drug: ABA, open-label (OL) | Intervention Type: DRUG; Name: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB); Assigned to Arm(s): Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) | Intervention Type: DRUG; Name: Infliximab (INF) + MTX, DB; Assigned to Arm(s): Infliximab + MTX (DB) | Intervention Type: DRUG; Name: Placebo (PLA) + MTX, DB; Assigned to Arm(s): Placebo + MTX (DB) | Intervention Type: DRUG; Name: PLA + MTX switched to ABA+ MTX, DB; Assigned to Arm(s): Placebo + MTX switched to abatacept + MTX (DB) | Intervention Type: DRUG; Name: ABA, open-label (OL); Assigned to Arm(s): Abatacept (open-label)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
D: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Arm Label: Sequence 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 4

Answer: D